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Abstract
Background
Major depression is a prevalent mental disorder with a high risk of relapse or recurrence.
Only few studies have focused on the cost-effectiveness of interventions aimed at the pre-
vention of relapse or recurrence of depression in primary care.
Aim
To evaluate the cost-effectiveness of a supported Self-help Preventive Cognitive Therapy
(S-PCT) added to treatment-as-usual (TAU) compared with TAU alone for patients with a
history of depression, currently in remission.
Methods
An economic evaluation alongside a multi-center randomised controlled trial was performed
(n = 248) over a 12-month follow-up. Outcomes included relapse or recurrence of depres-
sion and quality-adjusted-life-years (QALYs) based on the EuroQol-5D. Analyses were per-
formed from both a societal and healthcare perspective. Missing data were imputed using
multiple imputations. Uncertainty was estimated using bootstrapping and presented using
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Results
S-PCT statistically significantly decreased relapse or recurrence by 15% (95%CI 3;28) com-
pared to TAU. Mean total societal costs were €2,114 higher (95%CI -112;4261). From a
societal perspective, the ICER for relapse or recurrence was 13,515. At a Willingness To
Pay (WTP) of 22,000 €/recurrence prevented, the probability that S-PCT is cost-effective, in
comparison with TAU, is 80%. The ICER for QALYs was 63,051. The CEA curve indicated
that at a WTP of 30,000 €/QALY gained, the probability that S-PCT is cost-effective com-
pared to TAU is 21%.
Conclusions
Though ultimately depending on the WTP of decision makers, we expect that for both relapse
or recurrence and QALYs, S-PCT cannot be considered cost-effective compared to TAU.
Introduction
Major depressive disorder (MDD) is a prevalent mental disorder that often runs an intermit-
tent lifelong course[1], is associated with a high risk of relapse or recurrence[2] and with fre-
quently incomplete remission between episodes[3–5]. It is considered to be among the most
disabling illnesses[6], and negatively affects many aspects of life[7–9].
Largely due to its recurrent nature, the economic consequences of MDD are substantial
[10–13]. It has been estimated that 1–2% of national healthcare expenses in Western countries
is spent on the treatment of depressive disorders[14,15]. Important factors contributing to the
considerable healthcare costs associated with depression are the high prevalence, early age of
onset and large risk of relapse or recurrence. However, the majority of costs associated with
MDD are due to loss of productivity [14,16–18]. Therefore, effective preventive interventions
may be beneficial from the viewpoint of patients and society [19,20]. However, these interven-
tions are mostly offered in secondary care, often relying on the intensive use of therapist’s
time, and, therefore, they are costly. A minimally supported self-help intervention may help to
overcome this problem.
A randomised clinical trial by Biesheuvel et al.[21] showed superior effect of a supported
Self-help Preventive Cognitive Therapy (S-PCT) plus treatment-as-usual (TAU) over TAU
alone in preventing relapse or recurrence in patients with a history of depressive episodes. Due
to the current economic down-turn and the scarcity of resources available for healthcare,
information on the cost-effectiveness of interventions is highly relevant for decision-makers.
Alongside this trial, we now investigate the cost-effectiveness of S-PCT compared with TAU
from both a societal and a healthcare perspective, in patients with a history of depression.
Methods
Design
An economic evaluation was performed alongside a pragmatic randomised controlled trial with
two parallel groups of participants. The design of this study is described in more detail else-
where [22]. The study is registered in the Dutch Trial Register, www.trialregister.nl, NTR3001.
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Ethics
The Medical Ethics Committee of the Vrije Universiteit medical center (VUmc) approved the
study protocol (S1 Protocol) and all participants provided written informed consent.
Terminology
To describe the course of depression, we use the operational criteria of Frank et al.[23].
According to these criteria, the course of depression is described as a series of disease stages in
which a patient can move from a symptom-free stage, to a stage characterised by some symp-
toms but not meeting the diagnostic criteria, to a stage with the full-blown disorder, after
which the patient can go into remission. When a patient stays in remission for a minimum of
six months, he or she is considered to be recovered. A relapse is defined as a depressive episode
that occurs during remission and before recovery, while a recurrence is defined as a depressive
episode that occurs after recovery.
Treatment allocation
Once participants had provided informed consent, they received the Structured Clinical Inter-
view for DSM-IV Axis 1 disorders 3.0 [24] (SCID-1 3.0) to assess eligibility criteria. When par-
ticipants were eligible, randomisation was conducted by an independent statistician using
computer-generated random numbers in blocks of size two. Participants were randomised on
the order in which their baseline SCID-1 3.0- was conducted by the researchers. Randomisa-
tion was stratified by the number of previous depressive episodes (2–3 episodes versus�4 epi-
sodes) because the number of previous episodes is associated with relapse or recurrence [25].
Randomisation was concealed from the assessors who conducted interviews during the obser-
vation period, as they were not informed about the participants’ randomisation status, and
participants were requested not to disclose randomisation status to the assessors.
Blinding
Interviewers were blind for randomization status of the participants during all measurements.
Due to the nature of the intervention, it was not possible to blind the participants. At the start
of each interview, participants were asked not to reveal their allocation status to the
interviewers.
Participants
Participants were recruited through general practices and mental health care services in the
Netherlands. To be included in the trial, participants had to a) be 18 years or older, b) be in
remission of recurrent MDD for at least two months, but no longer recovered than five years
according to the SCID-1 3.0) and c) have experienced two or more previous episodes of MDD.
The SCID-I 3.0 interview was conducted by telephone by trained researchers and psycholo-
gists. Exclusion criteria were severe cognitive impairments, current or past mania, hypomania
or psychosis, current alcohol or drug abuse, or insufficient mastery of the Dutch language.
Counsellors
Twenty-four counsellors (primary care mental health nurses and psychologists) were trained
to support the intervention. The psychologists were non-specialised psychologists (no postdoc-
toral training in clinical interventions). All counsellors attended a one-day training delivered
by experienced clinical psychologists, who developed the intervention and, therefore, had an
intimate knowledge of PCT. To detect competence issues, audiotaped telephone contacts with
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two participants of each counsellor were evaluated during a one-day supervision with the
trainer(s) before the actual start of the trial. During the trial, counsellors could contact the
trainers at any time for additional questions and feedback.
Intervention
The self-help preventive cognitive therapy is a manualised PCT-based bibliotherapy consisting
of a printed self-help book with eight modules and minimal guidance [26]. It is based on an
effective face-to-face PCT [27,28] and mobile PCT[29]. PCT for the prevention of depression
is an adapted type of Cognitive Therapy (CT) for acute depression[30] and aims to prevent
relapse or recurrence in remitted patients with a history of depressive episodes. Like regular
CT, PCT follows a fixed structure, with agenda setting, review of homework, explanation of
the rationale of each session, and the assignment of homework. Participants complete one
module per week. Each module includes both reading plus assignments to be completed in
approximately 60 minutes. During the first meeting (by phone or face-to-face), the counsellor
explained the rationale of S-PCT and the planning for the coming week. Each week the coun-
sellor contacted the participant by phone to evaluate progress and understanding. This call
was strictly protocolled and was designed to last no longer than 15 minutes. The nature of the
contact was solely to support the participant, and not to actively engage in a therapeutic rela-
tionship. Adherence to the intervention protocol was assessed using a checklist. Each week,
the counsellor completed this checklist with 4 items; (1) the number of that week’s module (1–
8), (2) did the participants read the literature of that week (yes/no plus reason), (3) did the par-
ticipant do the assignments (yes/no plus reason) and (4) time spent on the call (minutes).
Treatment-as-usual (TAU)
There were no restrictions to type of TAU. Care providers were not aware of randomization
status unless participants informed them. Current TAU guidelines suggest continuation of
antidepressant medication (ADM) for at least 6 months after remission[31]. People at signifi-
cant risk of relapse or recurrence, should be offered individual Cognitive (Behavourial)Ther-
apy (C(B)T) or Mindfulness-Based Cognitive Therapy (MBCT). TAU (e.g. ADM or
psychiatric counselling) was recorded using the Trimbos and iMTA questionnaire for costs
associated with Psychiatric Illnesses (TiC-P)[32].
Sample size
We combined findings from previous research [33,34] and assumed a mean relapse or recur-
rence rate of 40% during the 12-months observation period versus 60% in the controls. To
detect this 20% risk-reduction in a 2-sided test at α = 0.05 and a power of 1-β = 0.80, 107 par-
ticipants in each condition were required. Compensating for loss to follow-up of 10% over the
whole 12-month observation period, required at least (107/0.90 =) 119 participants at baseline
in each trial arm. Our own experience with randomization of patients at general practice level
[35,36] indicates that clustering of patients within practices has no impact on the power of the
trial. Therefore, we did not take clustering effects into account.
Clinical outcome measures
Relapse or recurrence. Primary outcome was the incidence of relapse or recurrence of
depression over the 12 months follow-up period. To reduce recall bias, the telephone SCID-1
3.0 was conducted at both 6 and 12 months and combined into a single outcome (0 = no
relapse or recurrence, 1 = relapse or recurrence).
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Quality of life. Health related quality of life (HRQoL) was evaluated using the Dutch
translations of the EuroQol-5D (three levels) questionnaire (EQ-5D-3L)[37]. The EQ-5D mea-
sures Health Related Quality of Life (HRQoL) on five dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety and depression), combined into one outcome. Each
dimension is rated at three levels corresponding to whether a respondent has no problems,
moderate or extreme problems. Utility scores for the EQ-5D health states were estimated
using preference weights obtained from the Dutch population [38]. Quality-adjusted life-years
(QALYs) were calculated by multiplying the utility scores belonging to a health state by the
amount of time spent in this health state using linear interpolation between time points.
Costs
Costs were assessed every 3 months during the 12-month follow-up period and categorised
into 8 groups: primary care costs (general practice visits), secondary care costs (including con-
sultations, day care and hospital days), mental health care costs (sessions with psychologists
and/ or psychiatrists in primary and secondary care), home care costs (formal help with
domestic tasks), medication costs, costs due to lost productivity, informal care costs (help
from family and friends) and intervention costs (costs of S-PCT).
Health care utilization costs. The TiC-P [32] was used to assess the utilization of formal
health care services (primary care, secondary medical care,) and informal care during the last 3
months. Costs were computed by multiplying the units of health care use (visits, consultations,
sessions, hospital days) by the standard cost prices of these services as reported in the Dutch
costing guideline[39]. Costs of medication were valued using daily defined doses (DDD) and
the cost prices of the Royal Dutch Society for Pharmacy [40] to which the pharmacist’s dis-
pensing costs were added. All costs were indexed for the year 2013.
Lost productivity costs. The TiC-P was used to measure productivity losses due to both
absenteeism (absent from work) and presenteeism (less productive at work). Costs of absentee-
ism from paid work were calculated according to both the human capital-, and the friction
cost approach, using the mean age-, and sex specific income of the Dutch population[41]. In
the human capital method, any hour not worked counts as an hour lost. By contrast, according
to the friction cost approach, a sick employee is replaced after a certain amount of time (the
friction period; currently 160 days) after which there are no longer productivity losses, because
the absent employee will be replaced by someone else. Costs of presenteeism were calculated
by asking participants how many working hours should have been replaced due to less produc-
tivity at work. Lost productivity due to presenteeism was valued using the mean age-, and sex
specific income of the Dutch population[41]. Costs of productivity losses due to absenteeism
from unpaid work and informal care were calculated using the standard wage of a professional
housekeeper[42]. Discounting was unnecessary, because neither costs nor benefits were
recorded beyond 12 months.
Cost price supported self-help PCT. A cost price for S-PCT was calculated using a bot-
tom-up approach. Cost price for S-PCT totaled €388.15 per recipient. The average costs of
screening the participants was estimated to be €46.12, consisting of 45 minutes of time by the
counsellor (€35.92) and the time spent by the participant to complete the interview (€10.20).
Costs that were included in the cost price calculation of S-PCT were the printing costs of the
bibliotherapeutic booklet including sending it by mail (€2.13), the costs of support and admin-
istration time invested by the counsellor (€ 143.67), telephone costs by the counsellor (€5.40)
the time costs by participants (on the phone €40.80 + assignments €54.40) and the per-partici-
pants costs associated with training (€63.75) and supervising (€31.88) the counsellor. We used
the time spent and the Dutch tariff (hour rate of psychologist) to calculate support costs and
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administration time of the counsellor. We deliberately included time costs by participants,
because in a self-help intervention, the idea is that much of the therapeutic work is done by the
participants themselves.
Missing data
Missing data on costs and outcomes were imputed using multiple imputations with chained
equations (MICE) using predictive mean matching and fully conditional specification in
STATA 12 [43,44]. An imputation model was created that contained variables related to miss-
ing data and variables that significantly differed at baseline between the groups. Ten imputed
datasets were created, resulting in loss of efficiency of less than 2.5% for all outcomes[43]. The
10 imputed datasets were analyzed separately and the results of the analyses were pooled using
Rubin’s rules[45].
Statistical analysis
The statistical analyses were conducted according to the intention-to-treat (ITT) principle. In
the cost-effectiveness analysis (CEA), we estimated Incremental Cost-Effectiveness Ratios
(ICERs) as the ratio of the difference in mean costs divided by the difference in mean effects
on depressive relapse or recurrence between S-PCT and TAU. In the cost-utility analysis
(CUA), the ICER was defined by the ratio of the difference in costs between the S-PCT and the
TAU group by the difference in QALYs. Clinical effects were adjusted for depressive symp-
toms at baseline, which is a main predictor of relapse or recurrence. Therefore, we added base-
line QIDS scores tot the Poisson regression model. Cost differences were adjusted for baseline
costs. Therefore, we added baseline costs to the regression model.
Seemingly unrelated regression was used to estimate differences in costs and effects while
accounting for potential correlation between costs and effects [46]. Costs generally have a
highly skewed distribution. Therefore, non-parametric bootstrapping with 5000 replications
was used to estimate bias-corrected and accelerated confidence intervals around cost differ-
ences[47] and to estimate uncertainty surrounding the ICERs. The bootstrapped cost-effect
pairs were plotted on a cost-effectiveness plane [48] and used to estimate cost-effectiveness
acceptability curves (CEACs). CEACs show the probability that the intervention is cost-effec-
tive in comparison with the control treatment for a range of ceiling ratios. The ceiling ratio is
defined as the amount of money society is willing to pay (WTP, λ) to gain one unit of effect
[49].
In the CEA, WTP-thresholds that were associated with probabilities of 80% and 95%, that
the intervention was cost-effective compared to TAU, were assessed. In the CUA, the probabil-
ities that the intervention was cost-effective in comparison with TAU at the commonly used
WTP thresholds of €20.000 and €30.000 were assessed [50].
All analyses were performed with STATA (version 12) and SPSS (IBM SPSS Statistics 20).
Sensitivity analyses
Two sensitivity analyses were performed. The first sensitivity analysis was performed from a
health care perspective (HC). From a healthcare perspective, which is used in countries like
the United Kingdom by the National Institute for Health and Clinical Excellence[31] (NICE),
only direct healthcare costs are included, thus excluding costs related to informal care and
costs related to lost productivity. In the per-protocol analysis (PP), statistical analysis was
restricted to patients who completed at least 80% if the intervention (n = 101 out of 124 inter-
vention participants).
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Results
Participants flow and recruitment
Details of enrolment are shown in Fig 1, according to the CONSORT recommendations (S1
Checklist). Recruitment took place between September 2012 and April 2014. Twenty-two
Fig 1. CONSORT flow diagram.
https://doi.org/10.1371/journal.pone.0208570.g001
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databases of primary care practices and 4 databases of specialised mental health care practices
were screened for eligible patients. This led to the selection of 5,489 potential participants who
received a short information letter. Finally, 248 patients met all inclusion-criteria and signed
informed consent. They were randomly allocated to the S-PCT group (124) or to the TAU
group (124). Complete effect data over 12 months follow-up were available for 81.5% (101/124
participants). Complete cost data over 12 months follow-up were available for 79.8% (99/124) of
the S-PCT patients and 75.8% (94/124) of the TAU patients. Participants without complete cost
data experienced significantly more fatigue (0.60, 95%CI: 0.09;1.10) at baseline. More informa-
tion about the pattern of missing data can be found in the article by Biesheuvel et al. [21].
Baseline characteristics
In Table 1, baseline socio-demographic, clinical characteristics and costs of the ITT group are
presented. Costs at baseline were assessed over the last three months.
Clinical outcomes
Clinical effects are presented in Table 2. In the S-PCT group, 44 participants (35%) experi-
enced a relapse or recurrence into a depression compared to 62 participants (50%) in the TAU
Table 1. Baseline characteristics and societal costs by allocation group.
Characteristics S-PCT (n = 124) TAU (n = 124) All (n = 248)
Age, mean (SD1; range) 48.6 (11.9; 20–76) 48.8 (11.4; 24–77) 48.7 (11.7; 20–77)
Females, n (%) 89 (71.8%) 84 (67.7%) 173 (69.8%)
Number of previous episodes, n (%)
- 2 or 3 66 (53.2%) 62 (49.9%) 64 (51.6%)
- 4 or more 58 (46.8%) 62 (50.1%) 60 (48.4%)
Marital status, n (%) (with partner) 80 (64.9%) 80 (64.9%) 80 (64.9%)
Education2, n (%) (high education) 53 (42.7%) 44 (35.5%) 48 (39.1%)
Age of onset, mean (SD1) 28.2 (11.4) 27.5 (12.3) 27.8 (11.9)
Depressive symptoms (QIDSsr), mean (SD1) 9.6 (4.8) 8.9 (5.0) 9.3 (4.9)
Quality of life
- Mental health (SF12, mean (SD1) 53.6 (12.2) 53.5 (11.6) 53.5 (11.9)
- Physical health (SF12, mean (SD1) 59.4 (11.4) 57.6 (11.7) 58.5 (11.6)
- EQ-5D (0–1), mean (SD1) 0.77 (0.21) 0.78 (0.20) 0.77 (0.20)
Comorbid psychopathology (4DSQ)
- Anxiety (0–24), median (IQR) 2 (4) 1 (5) 00) 2 (4)
- Distress (0–32), mean (SD1) 13.0 (7.6) 12.7 (8.0) 12.8 (7.8)
- Somatization (0–32), mean (SD1) 8.1 (5.5) 8.9 (5.7) 8.5 (5.6)
Pain (MPQ), median (IQR) 0 (4) 0 (6) 0 (6)
Fatigue (FSS; 1–7), mean (SD1) 3.8 (1.5) 3.9 (1.6) 3.8 (1.6)
Self-efficacy (GSES; 10–40), mean (SD1) 28.6 (5.9) 28.3 (6.2) 28.4 (6.0)
ADM use past 3 months, % 51.8% 56.7% 54.2%
Societal costs3 (SD1) 1,620 (3,370) 1,185 (2,405) 1,406 (2,944)
TAU, treatment-as-usual; SD, standard deviation; ADM, anti-depressant medication; MPQ, MacGill Pain Questionnaire; FSS, Fatigue Severity Scale; GSES, General Self
Efficacy Scale; EQ, EuroQol; QIDSsr, Quick Inventory of Depressive Symptoms self-report; 4DSQ, Four Dimensional Symptom Questionnaire; IQR, Interquartile
range.
1 Standard deviations were computed from the standard errors: (sd = sqrt (_b[var2] -_b[var]�_b[var]))
2 Education is defined as bachelor’s or master’s degree
3 Mean societal costs per person over three months prior to baseline, euros (€)
https://doi.org/10.1371/journal.pone.0208570.t001
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group over 12 months. This difference was statistically significant (risk difference 0.15, 95%CI
0.03;0.28). The mean pooled difference in QALYs in the S-PCT group compared to the TAU
group after 12 months was 0.03 (95%CI 0.0006;0.07).
Costs
Table 2 presents the multiply imputed and pooled cumulative annual costs in the S-PCT and
TAU group over 12 months. After adjustment for baseline costs, the difference in total costs
was €2,114 (95%CI -112;4261). For all cost-categories, mean costs for in the S-PCT group were
higher than in the TAU group, except for costs of mental health care. There were no patients
in the S-PCT group, nor in the TAU group who were absent for more than 160 subsequent
days during the 12-month follow-up. Therefore, results of the human capital approach equaled
the friction cost approach and are not reported separately.
Cost-effectiveness; primary results
The results of the CEA are presented in Table 3, Figs 2 and 3. The ICER for depressive relapse
or recurrence was 13,515, indicating that €13,515 should be invested to prevent 1 relapse or
recurrence in the S-PCT group in comparison with the TAU group. The CE-plane shows that
96% of the bootstrapped cost-effect pairs were located in the NE quadrant (more effective and
more expensive). The accompanying CEAC showed that the probability that the intervention
was considered cost-effective was 4% if WTP is 0 €/ relapse or recurrence prevented, 80% if
WTP is 22,000 €/ relapse or recurrence prevented, and 95% if WTP is 39,500 €/ relapse or
recurrence prevented.
Table 2. Multiply imputed pooled clinical outcomes and costs over 12-month follow-upa.
S-PCT (n = 124) TAU (n = 124) Difference 95%CIb
Clinical outcomes
Relapse or recurrence rate 0.35 0.50 0.15c 0.03;0.28
QALY 0.80 0.78 0.03c 0.0006;0.07
Annual costs (2013, euros)c
- Primary care, mean (SD) 648 (89) 517 (72) 131 -107;378
- Secondary care, mean (SD) 1,680 (462) 871 (250) 810 -40;2246
- Mental health care, mean (SD) 581 (85) 626 (110) -44 -351;179
- Home care, mean (SD) 127 (52) 117 (34) 10 -90;148
- Medication, mean (SD) 291 (34) 215 (26) 77 2.8;172
- Lost productivity, mean (SD) 3,919 (775) 2,538 (636) 1,381 -544;3148
absenteeism, mean (SD) 2,648 (521) 1,411 (468) 1,236 -119;2376
presenteeism, mean (SD) 1,271 (293) 1,127 (326) 144 -772;1086
Informal care, mean (SD)d 260 (36) 181 (25) 80 9;169
Intervention costs, mean (SD) 388 (39) 0 (0) 388 n/a
Total costs, unadjusted, mean (SD) 7,897 (1.015) 5,065 (960) 2,832 479;5497
S-PCT; supported self-help preventive cognitive therapy, QALY; Quality-Adjusted Life-Years, TAU; treatment-as-usual.
a Presented are means and mean differences
b 95% confidence intervals obtained by bias corrected and accelerated bootstrapping
c Annual costs per person, measured at the end of each three-month period during 12 months follow-up
d Informal care; care from family and friends
https://doi.org/10.1371/journal.pone.0208570.t002
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Table 3. Differences in relapse or recurrence and costs over 12 months between S-PCT and TAU; ICER, CE-planes quadrants, and acceptability.
Analysis
Outcome;
relapse or
recurrence
Costs Δa
(95% CI)
Effect Δb
(95% CI)
ICER Cost-
effectiveness
plane
Cost-
effectiveness
plane
Cost-
effectiveness
plane
Cost-
effectiveness
plane
Probability
that S-PCT is
cost-effective
compared to
TAU at WTP
of €0
Minimum
willingness to
pay for the
intervention to
be cost-effective
compared to
TAU at given
probabilities
Minimum
willingness to
pay for the
intervention to
be cost-effective
compared to
TAU at given
probabilities
NE SE SW NW 0.80 (80%) 0.95 (95%)
ITT analysis
(societal
perspective)
2,114
(-112;4261)
0.15
(0.03;0.28)
13,515 96% 3% 0% 1% 4% €22,000 €39,500
Per-protocol
analysis
(societal
perspective)
1,808
(-495;4025)
0.17
(0.03;0.30)
10,602 94% 5% 0% 1% 6% €17,500 €30,500
ITT analysis
(healthcare
system
perspective)
1,107
(75;2322)
0.15
(0.03;0.28)
7,079 97% 3% 0% 1% 4% €11,500 €21,500
CEA, cost-effectiveness analysis; CI, confidence interval; CUA, cost-utility analysis; ICER, incremental cost effectiveness ratio; ITT, intention-to-treat; NE, north east;
NW, north west; SE, south east; SW, south west; TAU, treatment-as-usual;WTP, willingness to pay
a Regression analysis; adjusted for baseline costs
b Poisson regression analysis, adjusted for depressive symptoms
https://doi.org/10.1371/journal.pone.0208570.t003
Fig 2. Scatter plot of estimated relapse of recurrence of incremental costs and incremental effects of S-PCT vs TAU
obtained by bootstrap re-sampling. NE; more expensive, more effective, SE; less expensive, more effective, SW; less
expensive, less effective, NW; more expensive, less effective.
https://doi.org/10.1371/journal.pone.0208570.g002
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Cost-utility; primary results
The results of the CUA are presented in Table 4, Figs 4 and 5. The ICER for QALYs was
63,051 indicating that €63,051 should be invested to gain 1 QALY in the S-PCT group as com-
pared to the TAU group. The CE-plane showed that 96% of QALY cost-effect pairs were
located in the NE quadrant (more effective and more expensive). The CEAC showed that the
probability that the intervention was considered cost-effective was 13% if WTP is 20.000
€/QALY gained and that this slowly increased to 21% if WTP is 30,000 €/QALY gained.
Fig 3. Cost-effectiveness acceptability curve for relapse of recurrence showing the probability that S-PCT is cost-
effective compared to TAU over a range of values for the maximum acceptable ceiling.
https://doi.org/10.1371/journal.pone.0208570.g003
Table 4. Differences in QALYs and costs over 12 months between S-PCT and TAU; ICER, CE-planes quadrants, and acceptability.
Analysis
Outcome;
QUALY
Costs Δa
(95% CI)
Effect Δb
(95% CI)
ICER Cost-
effectiveness
plane
Cost-
effectiveness
plane
Cost-
effectiveness
plane
Cost-
effectiveness
plane
Probability
that S-PCT is
cost-effective
compared to
TAU at WTP
of €0
Probability
that S-PCT is
cost- effective
compared to
TAU at given
WTP
Probability
that S-PCT is
cost- effective
compared to
TAU at given
WTP
NE SE SW NW WTP €0 WTP €20.000 WTP €30.000
ITT analysis
(societal
perspective)
2,114
(-112;4261)
0.03
(0.0006;0.07)
63,051 95% 3% 0% 2% 4% 13% 21%
Per-protocol
analysis
(societal
perspective)
1,808
(-495;4025)
0.04
(0.008:0.08)
41,952 94% 5% 0% 1% 6% 23% 36%
ITT analysis
(healthcare
system
perspective)
1,107
(75;2322)
0.03
(0.0006;0.07)
33,025 95% 3% 0% 2% 3% 28% 46%
CEA, cost-effectiveness analysis; CI, confidence interval; CUA, cost-utility analysis; ICER, incremental cost effectiveness ratio; ITT, intention-to-treat; NE, north east;
NW, north west; QALY, quality-adjusted-life-year; SE, south east; SW, south west; TAU, treatment-as-usual; WTP, willingness-to-pay
a Adjusted for baseline costs
b Linear mixed models, adjusted for depressive symptoms
https://doi.org/10.1371/journal.pone.0208570.t004
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Fig 4. Scatter plot of estimated QALY of incremental costs and incremental effects of S-PCT vs TAU obtained by
bootstrap re-sampling. NE; more expensive, more effective, SE; less expensive, more effective, SW; less expensive, less
effective, NW; more expensive, less effective.
https://doi.org/10.1371/journal.pone.0208570.g004
Fig 5. Cost-effectiveness acceptability curve for QALY showing the probability that S-PCT is cost-effective
compared to TAU over a range of values for the maximum acceptable ceiling.
https://doi.org/10.1371/journal.pone.0208570.g005
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Sensitivity analyses
The results of the sensitivity-analyses are presented in Table 3 (relapse or recurrence), and
Table 4 (QALY). The analysis from healthcare perspective showed that adjusted costs in the
S-PCT group were statistically significantly lower than in the TAU group (mean difference
€1,107, 95%CI 75;2322). The effect differences are the same as in the ITT analysis from the
societal perspective. The ICER for depressive relapse or recurrence was 7,079 indicating that
€7,079 should be invested to prevent 1 relapse or recurrence in the S-PCT group in compari-
son with the TAU group. The majority of the cost-effect pairs were again located in the NE
quadrant (97%). The accompanying CEAC showed that the probability that the intervention
was cost-effective was 4% if WTP is 0 €/ relapse or recurrence prevented, 80% if WTP is
11,500 €/ relapse or recurrence prevented, and 95% if WTP is 21,500 €/ relapse or recurrence
prevented. From a healthcare perspective, the ICER for QALYs was 33,025, indicating that
€33,025 should be invested to gain 1 QALY in the S-PCT group as compared to the TAU
group. The probability that S-PCT was considered cost-effective in comparison with TAU for
QALYs at WTP thresholds of €20.000 and €30.000 were 28% and 46%, respectively.
A per protocol (PP) analysis with only those participants who completed at least 80% (5
modules) of the intervention (81%; 101 out of 124 participants), showed a mean difference in
costs between the S-PCT group and the TAU group of €1,808 (95%CI €-495;4025). S-PCT
decreased relapse or recurrence by 17% (95%CI 3;30) and gained 0.04 QALY (95%CI
0.008;0.08) compared to the TAU group. The ICER for depressive relapse or recurrence was
10,602. Again, the cost-effect pairs were mostly located in the NE quadrant of the CE plane
(94%). The accompanying CEAC showed that the probability that the intervention was cost-
effective was 6% if WTP is 0 €/relapse or recurrence prevented, 80% if WTP is 17,500 €/relapse
or recurrence prevented, and 95% if WTP is 30,500 €/relapse or recurrence prevented. In the
PP analysis, the ICER for QALYs was 41,952. The probability that S-PCT was considered cost-
effective in comparison with TAU for QALYs at WTP thresholds of €20,000 and €30,000 were
23% and 36%, respectively.
Discussion
Main findings
We evaluated whether treatment-as-usual (TAU) augmented with a supported self-help Pre-
ventive Cognitive Therapy (S-PCT) in primary care was cost-effective in comparison with
TAU alone for patients with recurrent depression. In the S-PCT group, statistically signifi-
cantly fewer patients experienced a relapse or recurrence of depression than in the TAU
group. For QALYs, a statistically significant difference between the two conditions was also
observed, in favor of the S-PCT group. However, mean societal costs adjusted for baseline
costs were higher in the S-PCT group than in the TAU group over 12 months, though not sta-
tistically significantly. Willingness-to-pay values should be quite high to reach an acceptable
probability that S-PCT is considered cost-effective in comparison with TAU (80% at a WTP of
22,000 €/relapse or recurrence prevented). For the commonly accepted WTP value of 20,000
€/QALY gained, the probability that S-PCT was cost-effective in comparison with TAU was
13%. Sensitivity analyses showed similar results.
Interpretation and explanation of main findings
The main contributors to the difference in mean societal costs were the costs due to secondary
medical care (mental health care not included) and due to lost productivity. It is unclear how
these cost differences can be explained as there were no relevant differences in baseline
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characteristics, there were no clear outliers for costs and there was no association between
costs and relapse or recurrence in the S-PCT group.
Previous research shows that interventions (usually CBT) aimed at the prevention of the
onset of MDD in patients with sub-threshold depression (depressive symptoms but insufficient
to warrant MDD), generally show good value for money [51–55]. However, the few economic
evaluations of preventive interventions to reduce the risk of relapse or recurrence of MDD,
show mixed results. Stant et al. [56] found that TAU enriched with CBT might be cost-effective
in preventing relapses in primary care patients with depression compared to TAU alone. Psy-
chodynamic counselling for relapse prevention proved to be cost-effective in comparison with
usual care [57]. The study by Kuyken et al. [58] is the most recently published cost-effective-
ness analysis, indicating that MBCT plus the tapering of ADM is not cost-effective in compari-
son with maintenance ADM in terms of either relapse or recurrence or QALYs in patients
with a history of three or more depressive episodes and on a therapeutic dose of maintenance
antidepressant drugs medication at baseline. A closer look at their costs reveals that the mean
societal costs over 24 months per participant in the intervention group and control group in
the study by Kuyken et al. (₤3,204/€4,415 and ₤2,754/€3,795 respectively) were much lower
than the mean societal costs over 12 months per participant in our study (€7,897 and €5,065,
respectively). Kuyken et al. used other ways of measuring productivity losses and healthcare
costs, which might explain some of this difference. However, for example, their mean number
of fulltime days off work was half the number of days in our study. An explanation for this dif-
ference in days off work is lacking.
Strengths and limitations
This study has several strengths. To minimise recall bias, costs over the 12-month follow-up
were assessed with questionnaires at 3,6,9 and 12 months. Furthermore, our measurement of
depression was based on a well-validated and reliable structured clinical interview (Structured
Clinical Interview for DSM-IV Disorders-1)[25]. A further strength of this study is that the
trial participants achieved remission or recovery on antidepressants, other psychotherapies,
psychiatric help, counselling, or no treatment at all, as is typically the case in clinical practice.
Moreover, there were no restrictions in the use of medication at entry to the study. This was
done to maximise the external validity of the study, resulting in high generalizability of the
findings.
A limitation of our study is, as is common in studies on psychological interventions, that it
was not possible to blind participants to the condition to which they were assigned. Also, the
follow-period of 1 year might have been too short to capture all the changes in effects and costs
due to the intervention. Time to recurrence might exceed 12 months, possibly implying that
we have missed the interventions’ and TAUs’ impact on later recurrences and associated
health-economic consequences (such as productivity and health care use). Finally, we used the
EQ-5D to detect differences in health care status and to compare the outcomes with other
studies. However, the EQ-5D has shown to be less responsive and needs larger patient samples
to detect meaningful differences in patients with depression [59]. Though our sample includes
remitted patients, this limitation may have influenced the results and the clinical effects may
have been larger with another instrument.
Conclusions and future research
Our study shows that the larger effects of S-PCT are associated with higher costs as compared
to TAU. A WTP of 22,000 €/relapse or recurrence prevented to reach a 80% probability that
S-PCT is cost-effective in comparison with TAU is expected to be too high for decision
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makers. We recommend an extended follow-up in future studies and a more in-depth evalua-
tion of costs. Furthermore, we recommend offering S-PCT directly after treatment in the acute
phase [60]. In addition, it is crucial to study what works for whom.
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